MT2017-42: A Phase 1/2, Open-label, Single-arm Study to

Project: Research project

Project Details

Description

MT2017-42: A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-dependent Beta-thalassemia
StatusActive
Effective start/end date5/15/185/14/23

Funding

  • Sangamo Therapeutics, Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.